Evaluating Trends in Anaplastic Thyroid Cancer Patients' Clinical Study Experiences
Study Details
Study Description
Brief Summary
Clinical trials can sometimes favor certain demographic groups. Additionally, there is limited research that delves into the factors that influence participation in clinical study, both positive and negative.
The goal is to identify the obstacles and challenges that prevent participation in anaplastic thyroid cancer clinical research, as well as the reasons for withdrawal or discontinuation.
Insights gained from this study will ultimately benefit those with anaplastic thyroid cancer who may be invited to participate in clinical research in the years to come.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Study Design
Outcome Measures
Primary Outcome Measures
- Number of anaplastic thyroid cancer patients who decide to enroll in a clinical study [3 months]
- Rate of anaplastic thyroid cancer patients who remain in a clinical study to completion [12 months]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Diagnosed with anaplastic thyroid cancer
-
Willing to comply with all study related procedures and assessments
-
Capable of giving signed informed consent, which includes compliance with requirements and restrictions listed in the informed consent form (ICF) and in the protocol
Exclusion Criteria:
-
No documented diagnosis of anaplastic thyroid cancer
-
Any serious and/or unstable pre-existing medical disorders
-
Pregnant or lactating woman
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Power Life Sciences Inc.
Investigators
- Study Director: Michael B Gill, Power Life Sciences Inc.
Study Documents (Full-Text)
More Information
Publications
- Al-Jundi M, Thakur S, Gubbi S, Klubo-Gwiezdzinska J. Novel Targeted Therapies for Metastatic Thyroid Cancer-A Comprehensive Review. Cancers (Basel). 2020 Jul 29;12(8):2104. doi: 10.3390/cancers12082104.
- Ljubas J, Ovesen T, Rusan M. A Systematic Review of Phase II Targeted Therapy Clinical Trials in Anaplastic Thyroid Cancer. Cancers (Basel). 2019 Jul 4;11(7):943. doi: 10.3390/cancers11070943.
- Saini S, Tulla K, Maker AV, Burman KD, Prabhakar BS. Therapeutic advances in anaplastic thyroid cancer: a current perspective. Mol Cancer. 2018 Oct 23;17(1):154. doi: 10.1186/s12943-018-0903-0.
- 80865259